Licensed vaccine
Afluria Quadrivalent, Afluria Quadrivalent Southern Hemisphere
FDA-licensed vaccine · Seqirus Pty Ltd. · STN BL 125254
Key facts
| Trade name | Afluria Quadrivalent, Afluria Quadrivalent Southern Hemisphere |
|---|---|
| Proper name | Influenza Vaccine |
| Manufacturer | Seqirus Pty Ltd. |
| Submission tracking number (STN) | BL 125254 |
| FDA product areas | Biologics |
| Recent FDA documents | February 1, 2024 Approval Letter - AFLURIA, January 26, 2024 Approval Letter - Afluria Trivalent and Afluria Quadrivalent, June 30, 2023 Approval Letter - Afluria (trivalent) and Afluria Quadrivalent, April 7, 2023 Approval Letter - AFLURIA, July 1, 2022 Approval Letter - Afluria and Afluria Quadrivalent, February 17, 2022 Approval Letter - AFLURIA, July 2, 2021 Approval Letter - AFLURIA, March 4, 2021 Approval Letter - Afluria Quadrivalent, February 8, 2021 Approval Letter - Afluria, Package Insert - AFLURIA QUADRIVALENT SOUTHERN HEMISPHERE, August 27, 2020 Approval Letter - Afluria, July 2, 2020 Approval Letter - Afluria |
| FDA page updated | Feb 5, 2024 |
| FDA product page | fda.gov |
At a glance
- 10–99 FDA approval letters
- 10–99 Supporting documents
- 1–9 Product information documents
- Yes Document full text searchable in Orca1
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA-licensed vaccines
The FDA's CBER licenses vaccines for use in the United States. Each product page links the approval letters, package inserts and supporting documents for that vaccine.
Source: U.S. Food and Drug Administration (FDA), Center for Biologics Evaluation and Research (CBER), Vaccines Licensed for Use in the United States · Source date: